Latest news with #45thAnnualHealthcareConference
Yahoo
24-02-2025
- Business
- Yahoo
Revolution Medicines to Participate in March 2025 Investor Conferences
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in three upcoming investor conferences. Details of the company's participation are as follows: TD Cowen 45th Annual Healthcare Conference Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET Barclays 27th Annual Global Healthcare Conference Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET 2025 Leerink Partners Global Healthcare Conference Fireside Chat Date/Time: Wednesday, March 12 at 2:20 p.m. ET To listen to a live webcast of any of these events, or access archived webcasts, please visit: Following the live webcasts, replays will be available on the company's website for at least 14 days. About Revolution Medicines, Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company's pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit and follow us on LinkedIn. Revolution Medicines Media & Investor Contact:media@
Yahoo
20-02-2025
- Business
- Yahoo
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in two upcoming investment bank conferences. The TD Cowen 45th Annual Healthcare Conference is being held in Boston, MA, and the Leerink Global Healthcare Conference is taking place in Miami, FL. TD Cowen 45th Annual Healthcare Conference Fireside chat on Monday, March 3, 2025 at 11:10 a.m. Eastern Time Webcast link HERE Leerink Global Healthcare Conference Fireside chat on Monday, March 10, 2025 at 4:20 p.m. Eastern Time Webcast link HERE The live and archived webcasts will be accessible on the Events & Presentations page in the Investors section of the Crinetics' website at If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist, that is currently in development for the treatment of congenital adrenal hyperplasia and Cushing's disease. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors:Gayathri DiwakarHead of Investor Relationsgdiwakar@ (858) 345-6340 Media: Natalie BadilloHead of Corporate Communications nbadillo@ (858) 345-6075
Yahoo
20-02-2025
- Business
- Yahoo
HCA Healthcare, Inc. to Present at March Healthcare Conferences
NASHVILLE, Tenn., February 20, 2025--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA), is scheduled to present virtually at the following healthcare conferences: March 4, 2025 at 1:50pm ET at TD Cowen's 45th Annual Healthcare Conference. March 11, 2025 at 1:30pm ET at Barclays' 27th Annual Global Healthcare Conference. March 19, 2025 at 2:15pm ET at KeyBanc's 5th Annual Healthcare Forum. March 20, 2025 at 10:00am ET at Oppenheimer's 35th Annual Healthcare MedTech & Services Conference. A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company's website, Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company's website for the latest information. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation's leading providers of healthcare services comprising 190 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom. All references to "Company" and "HCA" as used throughout this release refer to HCA Healthcare, Inc. and its affiliates. View source version on Contacts INVESTOR CONTACT: Frank Morgan615-344-2688 MEDIA CONTACT: Harlow Sumerford615-344-1851 Sign in to access your portfolio
